

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

Assignment ID: PAT1650950

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
Yan Lavrovsky	11/15/2024
Alexey Repik	11/22/2024
Mikhail Samsonov	11/22/2024
Sergei Barbashov	11/15/2024
Vasily Ignatiev	11/22/2024
RECEIVING PARTY DATA	
Company Name:	R-Pharm Overseas, Inc.
Street Address:	505 Coast Blvd., Suite 102
City:	La Jolla
State/Country:	CALIFORNIA
Postal Code:	92037
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	17474718
CORRESPONDENCE DATA	
Fax Number:	6178790177
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	6177346511
Email:	ykorkhin@scitechlegal.com
Correspondent Name:	Dr. Yakov Michael Korkhin
Address Line 1:	P.O. Box 448
Address Line 4:	Brookline, MASSACHUSETTS 02446
ATTORNEY DOCKET NUMBER:	OVS-019US
NAME OF SUBMITTER:	Yakov Korkhin
SIGNATURE:	Yakov Korkhin
DATE SIGNED:	11/22/2024
Total Attachments: 6	
source=OVS-019US_Assignment_AR_VI_MS#page1.tiff	

source=OVS-019US_Assignment_AR_VI_MS#page2.tiff
source=OVS-019US_Assignment_SB_Signed#page1.tiff
source=OVS-019US_Assignment_SB_Signed#page2.tiff
source=OVS-019US_Assignment_YL_signed#page1.tiff
source=OVS-019US_Assignment_YL_signed#page2.tiff

ASSIGNMENT

WHEREAS, we, Yan Lavrovsky, residing at 1969 Zapo Street, Del Mar, California, United States; Alexey Repik, residing at 3 Osenniy Boulevard, Apt. 106, Moscow, Russian Federation; Mikhail Samsonov, residing at 74-6-77 Leningradsky prospect, Moscow, Russian Federation; Sergei Barbashov, residing at 1105 Quail Meadow, Irvine, California, United States; and Vasily Ignatiev, residing at 13 Skolkovskoye Shosse, Apt. 212, Moscow, Russian Federation; (hereinafter referred to as "Assignors"), jointly made an invention entitled "IL1-R1 DERIVED INHIBITOR OF IL-1 β AND USE THEREOF," for which an International Patent Application was filed on May 22, 2020, and accorded International Patent Application No. PCT/US2020/034114, and an application for a United States Patent was filed on September 26, 2016, and accorded U.S. Patent Application Serial No. 15/129,412 (now US Patent No. 11,155,600 issued on October 26, 2021), and an International Patent Application was filed on March 24, 2014, and accorded International Patent Application No. PCT/US2014/031622, and an application for a United States Patent was filed on September 14, 2021, and accorded U.S. Patent Application Serial No. 17/474,718, which claims priority to the above referenced International Patent Applications and US Patent Application.

WHEREAS, R-Pharm Overseas, Inc., a Delaware corporation, having its principal place of business at 505 Coast Blvd. So., Suite 102, La Jolla, California, United States (hereinafter referred to as "Assignee"), is desirous of acquiring right, title and interest in said invention.

NOW, THEREFORE, in consideration of One Dollar (\$1.00), and other good and valuable consideration, the receipt of which is hereby acknowledged, Assignors by these presents, do sell, assign and transfer to Assignee, Assignors' entire right, title and interest, for the United States of America and its possessions and territories and for all foreign countries, in and to said invention, including all rights of priority created and conferred by any treaty or international convention which is available in connection with said invention, including the right to apply for patent rights, U.S. or foreign, and in any continuations, divisions, substitutes, renewals, reissues or other applications filed in the U.S. or abroad (including multinational filing arrangements of all kinds), and in any U.S. or foreign patents issued on any such applications and reissues, extensions and renewals thereof, to be held and enjoyed by Assignee, for its own use and behalf and for its successors and assigns, to the full ends of the terms or extended terms for which any Letters Patents or the like may be granted, as fully and entirely as the same would have been held by Assignors had this sale, assignment and transfer not been made.

Assignors hereby authorize and request the Commissioner of Patents of the United States, and any official of any country or countries (including multinational filing arrangements of all kinds), whose duty it is to receive and/or examine applications for patents or similar intellectual/industrial property, issue patents or other evidence or forms of intellectual/industrial property protection on applications as aforesaid, to issue the same to Assignee, its successors and assigns, in accordance with the terms of this instrument.

Assignors covenant with Assignee, its successors, assigns, and legal representatives that Assignors have full right to convey the entire interest herein assigned, and that Assignors have

not executed any agreement in conflict herewith and will not execute any agreement or conveyance in conflict herewith.

Assignors further covenant and agree to communicate to Assignee, its successors, legal representatives and assigns, any facts known to Assignors respecting said invention, and testify in any legal proceeding, sign all lawful papers, including, without limitation, application papers, assignments, powers of attorney, declarations, and other instruments, execute all divisional, continuing, substitute, reissue, renewal and foreign applications, make all truthful oaths, declarations and statements, and generally do everything reasonably requested of Assignors by Assignee, or its successors or assigns to aid Assignee, its successors or assigns, to obtain, enforce and/or exploit said invention.

Executed this 22nd day of November, 2024.




Alexey Repik

Executed this 22nd day of November, 2024.



Mikhail Samsonov

Executed this 22nd day of November, 2024.



Vasily Ignatiev

ASSIGNMENT

WHEREAS, we, Yan Lavrovsky, residing at 1969 Zapo Street, Del Mar, California, United States; Alexey Repik, residing at 3 Osenniy Boulevard, Apt. 106, Moscow, Russian Federation; Mikhail Samsonov, residing at 74-6-77 Leningradsky prospect, Moscow, Russian Federation; Sergei Barbashov, residing at 1105 Quail Meadow, Irvine, California, United States; and Vasily Ignatiev, residing at 13 Skolkovskoye Shosse, Apt. 212, Moscow, Russian Federation; (hereinafter referred to as "Assignors"), jointly made an invention entitled "IL1-R1 DERIVED INHIBITOR OF IL-1 β AND USE THEREOF," for which an International Patent Application was filed on May 22, 2020, and accorded International Patent Application No. PCT/US2020/034114, and an application for a United States Patent was filed on September 26, 2016, and accorded U.S. Patent Application Serial No. 15/129,412 (now US Patent No. 11,155,600 issued on October 26, 2021), and an International Patent Application was filed on March 24, 2014, and accorded International Patent Application No. PCT/US2014/031622, and an application for a United States Patent was filed on September 14, 2021, and accorded U.S. Patent Application Serial No. 17/474,718, which claims priority to the above referenced International Patent Applications and US Patent Application.

WHEREAS, R-Pharm Overseas, Inc., a Delaware corporation, having its principal place of business at 505 Coast Blvd. So., Suite 102, La Jolla, California, United States (hereinafter referred to as "Assignee"), is desirous of acquiring right, title and interest in said invention.

NOW, THEREFORE, in consideration of One Dollar (\$1.00), and other good and valuable consideration, the receipt of which is hereby acknowledged, Assignors by these presents, do sell, assign and transfer to Assignee, Assignors' entire right, title and interest, for the United States of America and its possessions and territories and for all foreign countries, in and to said invention, including all rights of priority created and conferred by any treaty or international convention which is available in connection with said invention, including the right to apply for patent rights, U.S. or foreign, and in any continuations, divisions, substitutes, renewals, reissues or other applications filed in the U.S. or abroad (including multinational filing arrangements of all kinds), and in any U.S. or foreign patents issued on any such applications and reissues, extensions and renewals thereof, to be held and enjoyed by Assignee, for its own use and behalf and for its successors and assigns, to the full ends of the terms or extended terms for which any Letters Patents or the like may be granted, as fully and entirely as the same would have been held by Assignors had this sale, assignment and transfer not been made.


Assignors hereby authorize and request the Commissioner of Patents of the United States, and any official of any country or countries (including multinational filing arrangements of all kinds), whose duty it is to receive and/or examine applications for patents or similar intellectual/industrial property, issue patents or other evidence or forms of intellectual/industrial property protection on applications as aforesaid, to issue the same to Assignee, its successors and assigns, in accordance with the terms of this instrument.

Assignors covenant with Assignee, its successors, assigns, and legal representatives that Assignors have full right to convey the entire interest herein assigned, and that Assignors have not executed any agreement in conflict herewith and will not execute any agreement or conveyance in conflict herewith.

Assignors further covenant and agree to communicate to Assignee, its successors, legal representatives and assigns, any facts known to Assignors respecting said invention, and testify in any legal proceeding, sign all lawful papers, including, without limitation, application papers, assignments, powers of attorney, declarations, and other instruments, execute all divisional, continuing, substitute, reissue, renewal and foreign applications, make all truthful oaths, declarations and statements, and generally do everything reasonably requested of Assignors by

Assignee, or its successors or assigns to aid Assignee, its successors or assigns, to obtain, enforce and/or exploit said invention.

Executed this 15th day of November, 2024.


Sergei Barbashov

1 of 2

ASSIGNMENT

WHEREAS, we, Yan Lavrovsky, residing at 1969 Zapo Street, Del Mar, California, United States; Alexey Repik, residing at 3 Osennyi Boulevard, Apt. 106, Moscow, Russian Federation; Mikhail Samsonov, residing at 74-6-77 Leningradsky prospect, Moscow, Russian Federation; Sergei Barbashov, residing at 1105 Quail Meadow, Irvine, California, United States; and Vasily Ignatiev, residing at 13 Skolkovskoye Shosse, Apt. 212, Moscow, Russian Federation; (hereinafter referred to as "Assignors"), jointly made an invention entitled "IL1-R1 DERIVED INHIBITOR OF IL-1 β AND USE THEREOF," for which an International Patent Application was filed on May 22, 2020, and accorded International Patent Application No. PCT/US2020/034114, and an application for a United States Patent was filed on September 26, 2016, and accorded U.S. Patent Application Serial No. 15/129,412 (now US Patent No. 11,155,600 issued on October 26, 2021), and an International Patent Application was filed on March 24, 2014, and accorded International Patent Application No. PCT/US2014/031622, and an application for a United States Patent was filed on September 14, 2021, and accorded U.S. Patent Application Serial No. 17/474,718, which claims priority to the above referenced International Patent Applications and US Patent Application.

WHEREAS, R-Pharm Overseas, Inc., a Delaware corporation, having its principal place of business at 505 Coast Blvd. So., Suite 102, La Jolla, California, United States (hereinafter referred to as "Assignee"), is desirous of acquiring right, title and interest in said invention.

NOW, THEREFORE, in consideration of One Dollar (\$1.00), and other good and valuable consideration, the receipt of which is hereby acknowledged, Assignors by these presents, do sell, assign and transfer to Assignee, Assignors' entire right, title and interest, for the United States of America and its possessions and territories and for all foreign countries, in and to said invention, including all rights of priority created and conferred by any treaty or international convention which is available in connection with said invention, including the right to apply for patent rights, U.S. or foreign, and in any continuations, divisions, substitutes, renewals, reissues or other applications filed in the U.S. or abroad (including multinational filing arrangements of all kinds), and in any U.S. or foreign patents issued on any such applications and reissues, extensions and renewals thereof, to be held and enjoyed by Assignee, for its own use and behalf and for its successors and assigns, to the full ends of the terms or extended terms for which any Letters Patents or the like may be granted, as fully and entirely as the same would have been held by Assignors had this sale, assignment and transfer not been made.


Assignors hereby authorize and request the Commissioner of Patents of the United States, and any official of any country or countries (including multinational filing arrangements of all kinds), whose duty it is to receive and/or examine applications for patents or similar intellectual/industrial property, issue patents or other evidence or forms of intellectual/industrial property protection on applications as aforesaid, to issue the same to Assignee, its successors and assigns, in accordance with the terms of this instrument.

Assignors covenant with Assignee, its successors, assigns, and legal representatives that Assignors have full right to convey the entire interest herein assigned, and that Assignors have

not executed any agreement in conflict herewith and will not execute any agreement or conveyance in conflict herewith.

Assignors further covenant and agree to communicate to Assignee, its successors, legal representatives and assigns, any facts known to Assignors respecting said invention, and testify in any legal proceeding, sign all lawful papers, including, without limitation, application papers, assignments, powers of attorney, declarations, and other instruments, execute all divisional, continuing, substitute, reissue, renewal and foreign applications, make all truthful oaths, declarations and statements, and generally do everything reasonably requested of Assignors by Assignee, or its successors or assigns to aid Assignee, its successors or assigns, to obtain, enforce and/or exploit said invention.

Executed this 15th day of November, 2024.



Yan Lavrovsky